Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INITIATE: Venetoclax at ART Initiation in HIV
NCT07481175Phase 1Recruiting
- Start
- Apr 2026
- Primary completion
- Jan 2030
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of venetoclax in human immunodeficiency virus infection (HIV) (2 arms). Primary endpoints: Safety of venetoclax administration at 365 days and Frequency of peripheral blood CD4+ T cells containing intact HIV-DNA at 365 days. Started Apr 2026; status: recruiting.
02
Drugs
venetoclax
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07481175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07481175.